{
  "trial_id": "NCT02902965",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, race, ECOG performance status, number of prior lines of therapy, type of prior therapies received, serum monoclonal protein levels, urine monoclonal protein levels, hematologic function, hepatic function, renal function, presence of peripheral neuropathy, presence of plasma cell leukemia, presence of primary amyloidosis, presence of POEMS syndrome.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "ECOG performance status",
          "ECOG performance status"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "number of prior lines of therapy",
        "type of prior therapies received",
        "serum monoclonal protein levels",
        "urine monoclonal protein levels",
        "hematologic function",
        "hepatic function",
        "renal function",
        "presence of peripheral neuropathy",
        "presence of plasma cell leukemia",
        "presence of primary amyloidosis",
        "presence of POEMS syndrome"
      ]
    },
    "processed-gen-response": "Age, gender, race, ECOG performance status, number of prior lines of therapy, type of prior therapies received, serum monoclonal protein levels, urine monoclonal protein levels, hematologic function, hepatic function, renal function, presence of peripheral neuropathy, presence of plasma cell leukemia, presence of primary amyloidosis, presence of POEMS syndrome."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, ECOG performance status, Number of prior lines of therapy, Serum monoclonal protein (SPEP), Urine monoclonal protein (UPEP), Hematologic function, Hepatic function, Renal function, ",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "ECOG performance status",
          "ECOG performance status"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "Number of prior lines of therapy",
        "Serum monoclonal protein (SPEP)",
        "Urine monoclonal protein (UPEP)",
        "Hematologic function",
        "Hepatic function",
        "Renal function"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, ECOG performance status, Number of prior lines of therapy, Serum monoclonal protein (SPEP), Urine monoclonal protein (UPEP), Hematologic function, Hepatic function, Renal function"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Prior Lines of Therapy, Prior Bortezomib Exposure, Measurable Disease, Serum Monoclonal Protein, Urine Monoclonal Protein, Hematologic Function, Hepatic Function, Renal Function.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "ECOG Performance Status",
        "Prior Lines of Therapy",
        "Prior Bortezomib Exposure",
        "Measurable Disease",
        "Serum Monoclonal Protein",
        "Urine Monoclonal Protein",
        "Hematologic Function",
        "Hepatic Function",
        "Renal Function"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, Prior Lines of Therapy, Prior Bortezomib Exposure, Measurable Disease, Serum Monoclonal Protein, Urine Monoclonal Protein, Hematologic Function, Hepatic Function, Renal Function."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, ECOG performance status, number of prior lines of therapy, prior bortezomib exposure, measurable disease type (serum or urine), serum monoclonal protein level, urine monoclonal protein level, hematologic function (e.g. hemoglobin, platelet count), hepatic function (e.g. bilirubin, AST, ALT), renal function (e.g. creatinine, eGFR).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "number of prior lines of therapy",
        "prior bortezomib exposure",
        "measurable disease type (serum or urine)",
        "serum monoclonal protein level",
        "urine monoclonal protein level",
        "hematologic function (e.g. hemoglobin, platelet count)",
        "hepatic function (e.g. bilirubin, AST, ALT)",
        "renal function (e.g. creatinine, eGFR)"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, ECOG performance status, number of prior lines of therapy, prior bortezomib exposure, measurable disease type (serum or urine), serum monoclonal protein level, urine monoclonal protein level, hematologic function (e.g. hemoglobin, platelet count), hepatic function (e.g. bilirubin, AST, ALT), renal function (e.g. creatinine, eGFR)."
  }
}